Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Resmed (RMD) stock in plain English

Free brief · no signupStart here
RMDPublished Nov 12, 2026
Resmed Inc
Healthcare · Medical Instruments & Supplies
Manufactures continuous positive airway pressure machines, respiratory masks, and digital sleep monitoring systems.
Assets:
20M+ connected devicescloud ecosystem tracking patient therapy compliance daily
AirTouch and AirFit masksreplacement cushions and headgear driving recurring high-margin sales
AirSense serieshome sleep therapy machines manufactured in global production hubs
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

83
OPS ScoreOperating finances
Latest quote
-2.36%$236.88
$33.32B
21.6×
$5.73B

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 12, 2026Quotes updated Nov 20, 04:00 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was RMD. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Resmed (RMD) do?

Resmed Inc (RMD) is a U.S.-listed company in Healthcare (Medical Instruments & Supplies). What it does: Manufactures continuous positive airway pressure machines, respiratory masks, and digital sleep monitoring systems. Connects millions of sleep apnea devices to proprietary cloud monitoring software for automated replacement supply. It is worth $33.32B on the market and sold $5.73B over the last year.

Market cap
$33.32B
P/E ratio
21.6×
Annual sales
$5.73B
Sector
Healthcare
Industry
Medical Instruments & Supplies
Brief updated
Nov 12, 2026

Brands and businesses behind RMD

  • AirSense: CPAP device line selling bedside sleep therapy machines with built-in cellular connectivity to clinics and distributors.
  • AirFit: CPAP mask family generating recurring revenue through prescribed periodic silicone cushion and frame replacements.
  • AirTouch: Memory foam CPAP mask line generating recurring sales through monthly disposable cushion replacements.
  • AirView: Cloud-based clinical management system earning recurring service fees from healthcare providers monitoring therapy data.
  • myAir: Patient engagement application and web portal that tracks sleep scores to encourage long-term equipment use.

RMD’s flags, in plain English

Each flag is a number from Resmed’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 12, 2026.

Low debt

Low debt, only 10% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Stupid Cash

Can pay this year's bills 2.7 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Fat Margins

Profit margin of 27.8%. The company keeps a healthy share of each sale as profit, which gives it room when costs jump.

Worth a Look

Expanding public use of GLP-1 weight loss medications creates competitive uncertainty around long-term sleep apnea hardware demand. Something here could change the picture, so it is worth reading next to the good news.

2 more green flags open with the free trial. Try it free for 7 days.

Questions about RMD

How big is Resmed?

Resmed’s market cap is $33.32B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $5.73B: what customers paid the company over the last year, before any costs.

What is RMD’s P/E ratio?

RMD’s P/E ratio is 21.6×. Investors pay about 21.6 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with RMD?

The first risk note on the card is Worth a Look, explained above. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Resmed’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. RMD’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card